NASDAQ:VINC - Nasdaq - US92731L1061 - Common Stock
Curious about the stocks that are showing activity after the closing bell on Thursday?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Thursday's after hours session: top gainers and losers
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Which stocks have an unusual volume on Tuesday?
Curious about the stocks that are showing activity after the closing bell on Monday?
Most active stocks in Monday's session
Top movers analysis in the middle of the day on 2024-12-30: top gainers and losers in today's session.
The market is buzzing with gapping stocks on Monday. Let's uncover which stocks are experiencing notable gaps during today's session.
The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company’s pipeline...
Also Exploring Strategic Alternatives to Complement Fundraising Efforts...
Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data...
VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the...
VINC stock results show that Vincerx Pharma beat analyst estimates for earnings per share the second quarter of 2024.
Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule...
VINC stock results show that Vincerx Pharma missed analyst estimates for earnings per share the first quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vincerx Pharma (NASDAQ:VINC) just reported results for the first quarter of 202...
Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236,...
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering...
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of...
Laser Photonics stock is rising higher on Tuesday as LASE investors celebrate a new unit order from L3Harris Technologies.
Vivos Therapeutics stock is up on Tuesday as VVOS investors react to the company securing full Medicare reimbursement for its OSA device.